Increased efficacy of brentuximab vedotin (SGN-35) in combination with cytokine-induced killer cells in lymphoma

International Journal of Molecular Sciences

Volumn 17, Issue 7, 2016, Pages

  Esser, Laura ^a   Weiher, Hans ^b   Schmidt Wolf, Ingo ^a  

^a UNIVERSITY OF BONN   (Germany)

^b BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Antibody drug conjugate; CD30+ cells; Cytokine induced killer (CIK) cells; Lymphoma; SGN 35

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD30 ANTIGEN; GAMMA INTERFERON;

ANIMAL CELL; ARTICLE; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IC50; LYMPHOMA; MTT ASSAY; NONHUMAN; APOPTOSIS; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; TUMOR CELL LINE;

ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNOCONJUGATES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOMA;

EID: 84977515199     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17071056     Document Type: Article

References (18)

1. Croager, E.J.; Gout, A.M.; Abraham, L.J. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am. J. Pathol. 2000, 156, 1723-1731. [CrossRef]
2. Buglio, D.; Mamidipudi, V.; Khaskhely, N.M.; Brady, H.; Heise, C.; Besterman, J.; Martell, R.E.; MacBeth, K.; Younes, A. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br. J. Haematol. 2010, 151, 387-396. [CrossRef] [PubMed]
3. Press, O.W.; Leonard, J.; Coiffier, B.; Levy, R.; Timmerman, J. Immunotherapy of Non-Hodgkin’s lymphomas. ASH Hematol. 2001, 1, 221-240. [CrossRef]
4. Wu, J.; Fu, J.; Zhang, M.; Liu, D. Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J. Hematol. Oncol. 2015, 8, 104. [CrossRef] [PubMed]
5. Wu, J.; Fu, J.; Zhang, M.; Liu, D. AFM 13: A first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J. Hematol. Oncol. 2015, 8, 96. [CrossRef] [PubMed]
6. Fan, G.;Wang, Z.; Hao, M.; Li, J. Bispecific antibodies and their applications. J. Hematol. Oncol. 2015, 8, 130. [CrossRef] [PubMed]
7. Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E.; et al. cAC10-vcMMAE, An anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458-1465. [CrossRef] [PubMed]
8. De Claro, R.A.; McGinn, K.; Kwitkowski, V.; Bullock, J.; Khandelwal, A.; Habtemariam, B.; Ouyang, Y.; Saber, H.; Lee, K.; Koti, K.; et al. US food and drug administration approval summary: Brentuximab vedotin for the treatment of relapsed hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin. Cancer Res. 2012, 18, 5845-5849. [CrossRef] [PubMed]
9. Bartlett, N.L.; Chen, R.; Fanale, M.A.; Brice, P.; Gopal, A.; Smith, S.E.; Advani, R.; Matous, J.V.; Ramchandren, R.; Rosenblatt, J.D.; et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J. Hematol. Oncol. 2014, 7, 24. [CrossRef] [PubMed]
10. Schmidt-Wolf, I.G.; Negrin, R.S.; Kiem, H.P.; Blume, K.G.; Weissmann, I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 1991, 174, 139-149. [CrossRef] [PubMed]
11. Linn, Y.C.; Lau, L.C.; Hui, K.M. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br. J. Haematol. 2002, 116, 78-86. [CrossRef] [PubMed]
12. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 2001, 97, 2923-2931. [CrossRef] [PubMed]
13. + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118, 3301-3310. [CrossRef] [PubMed]
14. Younes, A.; Gopal, A.K.; Smith, S.E.; Ansell, S.M.; Rosenblatt, J.D.; Savage, K.J.; Ramchandren, R.; Bartlett, N.L.; Cheson, B.D.; de Vos, S.; et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012, 30, 2183-2189. [CrossRef] [PubMed]
15. Wang, Y.; Xu, Z.; Zhou, F.; Sun, Y.; Chen, J.; Li, L.; Jin, H.; Qian, Q. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp. Hematol. Oncol. 2015, 4, 32. [CrossRef] [PubMed]
16. Slater, T.F.; Sawyer, B.; Straeuli, U. Studies on succinate-tetrazolium reductase systems. Points of coupling of four different tetrazolium salts. Biochim. Biophys. Acta 1963, 77, 383-393. [CrossRef]
17. Qian, S.; Shi, P.; Xie, Y.; Xu, Y.; Gao, D.; Liu, L.; Huang, X.; Chen, K.; Tan, J. Clinical study of autologous cytokine-induced killer cells for the consolidation treatment of elderly patients with diffuse large B-Cell lymphoma. Blood 2014, 124, 4463.
18. Zinzani, P.L.; Viviani, S.; Anastasia, A.; Vitolo, U.; Luminari, S.; Zaja, F.; Corradini, P.; Spina, M.; Brusamolino, E.; Gianni, A.M.; et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013, 98, 1232-1236. [CrossRef] [PubMed]